|
Citation
|
Jones CMP, Day RO, Koes BW, Latimer J, Maher CG, McLachlan AJ, Billot L, Shan S, Lin CWC, McLachlan H, Webb M, Hamilton M, Ahedi H, Barber A, Mak W, Mathieson S, Petrova V, Bompoint S, Shan S, Murnion B, Buckley N, Demirkol A, Wrigley P, Needs C, Brooks L, Cantori S, Preisz P, Aitken J, Allan S, Burke M, Cameron G, Cepeda FJV, Davis C, Dullur J, Emmanuel J, Errey C, Fieuw-Makaroff S, Gaudry A, Genua L, Longhurst I, McCroary K, Merhi D, Nguyen T, Obayd ZR, Penm M, Pobbathi S, Poh WS, Schnitzler P, Shahnaz S, Tan V, Tang D, Tan B, Thu WK, Triantopolous T, Venkatesan R, Wong WCF, Yang SC. Lancet 2023; ePub(ePub): ePub. |
|
Abstract
|
Background
Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce. We aimed to investigate the efficacy and safety of a judicious short course of an opioid analgesic for acute low back pain and neck pain.
Methods
OPAL was a triple-blinded, placebo-controlled randomised trial that recruited adults (aged ≥18 years) presenting to one of 157 primary care or emergency department sites in Sydney, NSW, Australia, with 12 weeks or less of low back or neck pain (or both) of at least moderate pain severity. Participants were randomly assigned (1:1) using statistician-generated randomly permuted blocks to guideline-recommended care plus an opioid (oxycodone-naloxone, up to 20 mg oxycodone per day orally) or guideline-recommended care and an identical placebo, for up to 6 weeks. The primary outcome was pain severity at 6 weeks measured with the pain severity subscale of the Brief Pain Inventory (10-point scale), analysed in all eligible participants who provided at least one post-randomisation pain score, by use of a repeated measures linear mixed model. Safety was analysed in all randomly assigned eligible participants. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615000775516).
Findings
Between Feb 29, 2016, and March 10, 2022, 347 participants were recruited (174 to the opioid group and 173 to the placebo group). 170 (49%) of 346 participants were female and 176 (51%) were male. 33 (19%) of 174 participants in the opioid group and 25 (15%) of 172 in the placebo group had discontinued from the trial by week 6, due to loss to follow-up and participant withdrawals. 151 participants in the opioid group and 159 in the placebo group were included in the primary analysis. Mean pain score at 6 weeks was 2·78 (SE 0·20) in the opioid group versus 2·25 (0·19) in the placebo group (adjusted mean difference 0·53, 95% CI -0·00 to 1·07, p=0·051). 61 (35%) of 174 participants in the opioid group reported at least one adverse event versus 51 (30%) of 172 in the placebo group (p=0·30), but more people in the opioid group reported opioid-related adverse events (eg, 13 [7·5%] of 174 participants in the opioid group reported constipation vs six [3·5%] of 173 in the placebo group).
Interpretation
Opioids should not be recommended for acute non-specific low back pain or neck pain given that we found no significant difference in pain severity compared with placebo. This finding calls for a change in the frequent use of opioids for these conditions.
Funding
National Health and Medical Research Council, University of Sydney Faculty of Medicine and Health, and SafeWork SA.
Language: en |